How Climate Change and Air Pollution Affect Kids ’ Health
Climate change affects everyone, but especially children. Their small bodies—and the fact that they grow so rapidly, starting from the time they’re in utero—make them more vulnerable to toxins, pollution, and other climate-change fallout. Over their lifetimes, kids also face greater exposure to the damage of climate change than adults. A new scientific review article published in the New England Journal of Medicine shows just how dangerous climate-related threats are to children’s health. The researchers analyzed data about the specific effects of a rapidly warming planet and found that climate chan...
Source: TIME: Health - June 17, 2022 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized healthscienceclimate Public Health Source Type: news

How cannabis-fed chickens may help cut Thai farmers ’ antibiotic use
Scientists observed fewer cases of avian bronchitis and superior meat after chickens given cannabisIt all began when Ong-ard Panyachatiraksa, a farm owner in the north of Thailand who is licensed to grow medicinal cannabis, was wondering what to do with the many excess leaves he had amassed. He asked: could his brood of chickens benefit from the leftovers?Academics at Chiang Mai University were also curious. Since last January they have studied 1,000 chickens at Ong-ard ’s Pethlanna organic farm, in Lampang, to see how the animals responded when cannabis was mixed into their feed or water.The results are promising and su...
Source: Guardian Unlimited Science - June 15, 2022 Category: Science Authors: Rebecca Ratcliffe in Bangkok Tags: Thailand Cannabis Chicken Asia Pacific Food Antibiotics Environment Drugs Farming Farm animals World news Society Science Source Type: news

AHA News: She Thought She Had Bronchitis, But the Problem Was Her Heart
Title: AHA News: She Thought She Had Bronchitis, But the Problem Was Her HeartCategory: Health NewsCreated: 6/13/2022 12:00:00 AMLast Editorial Review: 6/14/2022 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - June 14, 2022 Category: Cardiology Source Type: news

New Data Show Patients Treated with First-in-Class TREMFYA ® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years
SPRING HOUSE, PENNSYLVANIA, June 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with TREMFYA® (guselkumab) achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis,a dactylitis,b spinal pain and disease severityc endpoints – irrespective of baseline characteristics.1 Further analyses showed TREMFYA also provided patients with sustained improvements in measures of health-related quality of life (HRQoL), including fatigue, pain...
Source: Johnson and Johnson - June 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

6 steps you can take to quit smoking and live a healthier life
Cigarette smoking is highly addictive and can lead to health issues like bronchitis and lung cancer. Fortunately, there are strategies to stop smoking. (Source: CNN.com - Health)
Source: CNN.com - Health - May 31, 2022 Category: Consumer Health News Source Type: news

FDA approves Roche ’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walkPrescribing information updated with FIREFISH data showing the majority of symptomatic babies treated withEvrysdi for at least two years could sit for at least five secondsEvrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to dateBasel, 31 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under...
Source: Roche Media News - May 31, 2022 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walkPrescribing information updated with FIREFISH data showing the majority of symptomatic babies treated withEvrysdi for at least two years could sit for at least five secondsEvrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to dateBasel, 31 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under...
Source: Roche Investor Update - May 31, 2022 Category: Pharmaceuticals Source Type: news

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

New Data Show TREMFYA ® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
SPRING HOUSE, PENNSYLVANIA, May 18, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a hypothesis that may differentiate the mechanism of first-in-class TREMFYA® (guselkumab) from risankizumab due to the ability of TREMFYA to bind to CD64 positive (CD64+) cells in addition to interleukin (IL)-23 — both of which are key components of the immune system. 1,2 These findings, which are being presented at the Society for Investigative Dermatology (SID) annual meeting May 18-21, 2022 in Portland, Oregon, demonstrate TREMFYA bind...
Source: Johnson and Johnson - May 18, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA ® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatment History
SPRING HOUSE, PENNSYLVANIA, March 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced its first-in-class interleukin (IL)-23 inhibitor TREMFYA® (guselkumab) provided a consistent, high degree of durable skin clearance through five years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO) in the Phase 3 VOYAGE 1 and VOYAGE 2 clinical trials.1 A separate post hoc analysis of the VOYAGE studies showed TREMFYA provided high rates of efficacy and durability through five years and similar safety outcomes among patients with and without...
Source: Johnson and Johnson - March 25, 2022 Category: Pharmaceuticals Source Type: news

Janssen Initiates First-of-its-Kind Clinical Study to Bridge Critical Gaps in Care for People of Color with Moderate to Severe Plaque Psoriasis
HORSHAM, PENNSYLVANIA, March 22, 2022 – Psoriasis (PsO) can take a physical, psychological, and emotional toll on the more than 8 million Americans living with the disease; and for people of color, there are additional challenges due to limited medical research and education, as well as underrepresentation in clinical studies.1,2,3 This has led to a lack of data and barriers to optimal care for diverse patient populations.2 PsO may also present with less noticeable skin reddening on darker skin tones, which can make it harder for healthcare providers to identify and lead to misdiagnoses in people of color. To help addres...
Source: Johnson and Johnson - March 23, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves first generic of Symbicort to treat asthma and COPD
Today, the U.S. Food and Drug Administration approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions: asthma in patients six years of age and older; and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. (Source: World Pharma News)
Source: World Pharma News - March 15, 2022 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Chronic Bronchitis Increases Mortality Risk in Ever-Smokers Chronic Bronchitis Increases Mortality Risk in Ever-Smokers
Non-obstructive chronic bronchitis in ever-smokers may be associated with progression to COPD and thus increases mortality risk.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 2, 2022 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Zydus Pharmaceuticals (USA) Inc gets final US FDA approval to market Roflumilast tablets
Roflumilast tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations, it added. The group now has 327 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 14, 2022 Category: Pharmaceuticals Source Type: news

Gala Therapeutics Announces First Commercial Cases Worldwide with RheOx(R) System for Chronic Bronchitis
RheOx targets challenging cough and mucus symptoms by delivering non-thermal pulsed energy to the airways SAN CARLOS, Calif., Feb. 8, 2022 -- (Healthcare Sales & Marketing Network) -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to tr... Devices Gala Therapeutics, RheOx, Bronchial Rheoplasty System, chronic bronchitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 8, 2022 Category: Pharmaceuticals Source Type: news